Rising Transplants and Autoimmune Diseases Fuel Immunosuppressive Drug Market Growth to $69.3 Billion by 2035

Immunosuppressive drug market was valued at $41.8 billion in 2025 and is expected to expand to $69.3 billion by 2035, registering a CAGR of 5.2% over the 2026–2035 forecast period. The increasing volume of organ transplant procedures globally and the rising prevalence of autoimmune diseases are major drivers for the immunosuppressive drug market. Solid organ transplant recipients require lifelong immunosuppressive therapy to prevent graft rejection, while individuals living with autoimmune conditions depend on these drugs to control immune-mediated inflammation and disease progression. As transplant activity expands and more people are diagnosed with autoimmune disorders, demand for calcineurin inhibitors, mTOR inhibitors, antiproliferative agents, steroids, and other immunosuppressive drugs continues to grow across hospitals and specialty treatment centers globally.

Browse the full report description of “Immunosuppressive Drug Market Size, Share & Trends Analysis Report by Application (Autoimmune Diseases, Organ Transplant, and Other Applications), by Drug Class (Calcineurin Inhibitor, Antiproliferative Agent, mTOR Inhibitors, Steroids, and Other), by Drug Type (Patented, and Generic) Forecast Period, (2026-2035)” of  https://www.omrglobal.com/industry-reports/immunosuppressive-drug-market

Latest data show transplant volumes rising and autoimmune disease prevalence broadening the clinical base for immunosuppressive use. According to the Global Observatory on Donation and Transplantation, more than 173,700 solid organ transplants were performed globally in 2024, including over 110,000 kidney transplants and more than 42,000 liver transplants. Separately, findings reported by the Sjögren’s Foundation indicate that over 50 million Americans (around 8% of the US population) are affected by autoimmune diseases, with current data showing that prevalence is increasing. Women represent approximately 80% of all autoimmune cases, highlighting demographic patterns relevant for long-term therapeutic use.

Recent Product Launches, Approvals, and Strategic Moves in the Immunosuppressive Drug Market

• In October 2025, NATCO Pharma launched Everolimus 1mg tablets, a generic version of Novartis' Zortress, in the US through its partner Breckenridge Pharmaceutica. Everolimus, an mTOR inhibitor immunosuppressant, is used to prevent organ rejection in adult kidney and liver transplant patients.

• In May 2025, Teva Pharmaceuticals and Alvotech announced FDA approval of SELARSDI (ustekinumab-aekn) as interchangeable with Stelara (ustekinumab). SELARSDI matches all presentations of Stelara and is approved for treating adults and pediatric patients with psoriatic arthritis, plaque psoriasis, Crohn’s disease, and ulcerative colitis.

• In February 2025, Nexus Pharmaceuticals announced FDA approval of Tacrolimus Injection 5 mg/mL, the first and only vial available in this form. Tacrolimus is vital for immunosuppressive therapy to improve patient outcomes and reduce organ rejection risk.

• In July 2024, Biogen Inc. completed its acquisition of Human Immunology Biosciences (HI-Bio), a clinical-stage biotech company specializing in targeted therapies for severe immune-mediated diseases.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  • Application
  • Drug Class
  • Drug Type
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape – Astellas Pharma Inc., F. Hoffmann-La Roche Ltd., Novartis AG, Pfizer Inc., Sanofi S.A., among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Immunosuppressive Drug Market Report Segment

By Application

• Autoimmune Diseases
• Organ Transplant
• Other Applications

By Drug Class

• Calcineurin Inhibitor
• Antiproliferative Agent
• mTOR Inhibitors
• Steroids
• Others

By Drug Type

• Patented
• Generic

Global Immunosuppressive Drug Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

 To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/immunosuppressive-drug-market